Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
life sciences
national blog main
sanofi
10
×
boston top stories
national top stories
clinical trials
new york blog main
san francisco blog main
biotech
new york top stories
deals
san francisco top stories
cancer
fda
ipo
new york
startups
alnylam pharmaceuticals
amgen
boston
cancer drugs
investing
venture capital
drug discovery
inclisiran
national
novartis
pcsk9
regeneron pharmaceuticals
revolution medicines
rna interference
san francisco
takeda pharmaceutical
the column group
third rock ventures
vc
warp drive bio
abbvie
agios pharmaceuticals
What
medicines
10
×
drug
ipo
announced
cancer
deal
new
bets
bio
ceo
cholesterol
disease
latest
medco
medicine
molecules
pharmaceutical
proteins
research
revolution
rna
sanofi
targets
therapeutics
years
aces
acquire
acquisitions
address
adds
ago
agreed
allosteric
aren’t
backs
big
billion
brings
cancer’s
car
Language
unset
Current search:
sanofi
×
medicines
×
@xconomy.com
3 years ago
HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers
@xconomy.com
4 years ago
Schrödinger Sets Course for IPO to Support Growing Internal Pipeline
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing
@xconomy.com
5 years ago
Sanofi Backs Click Therapeutics as Digital Medicines Gain Momentum
@xconomy.com
5 years ago
With $45M Translate Bio Deal, Sanofi Bets Again on mRNA Vaccines
@xconomy.com
5 years ago
CAR-T’s Launch, Payers vs. Gene Therapy & Photos From “What’s Hot”